OraSure Q3 operating loss narrows 19% year over year to $12.96 million

By Public Technologies
  • OraSure Technologies’ third-quarter 2026 net loss narrowed year-over-year to $13.09 million.
  • Net revenues rose 14% year-over-year to $30.91 million, while gross margin improved to 45.2%.
  • Commercial launches of Colli-Pee Dx and OraQuick Ebola 2.0 generated initial orders during the quarter.
  • Fourth-quarter 2026 net revenues are forecast at $30 million-$32 million, with faster full-year growth expected in 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OraSure Technologies Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611091605PRIMZONEFULLFEED9873625) on November 09, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.